Estrogen receptor alpha (ERα) and progesterone receptor (PR) are important steroid
hormone receptor biomarkers used to determine prognosis and to predict benefit from …

Estrogen receptor (ER) and progesterone receptor (PR) are important prognostic and
predictive biomarkers in breast cancer. PET using ER-and PR-specific radioligands enables …

Many breast cancers express high levels of estrogen receptors (ER) or progesterone
receptors (PR), which have both been linked with the pathogenesis of this disease. Estrogen …

Molecular imaging using FES and FFNP PET can assess in vivo function of steroid hormone
receptors in breast cancer. These experimental agents have been tested in many single …

Current statistics show there are 3.5 million women in the United States living with breast
cancer today, and approximately 330,000 new cases are diagnosed each year. Of these …

Breast cancer is a commonly occurring disease in women and a major cause of morbidity
and mortality. In the past decades, the development of medical endocrine therapies has led …

Estrogen receptor-α (ERα) and progesterone receptor (PR) are expressed in most human
breast cancers and are important predictive factors for directing therapy. Because of de novo …

The vast majority of breast and prostate cancers express specific receptors for steroid
hormones, which play a pivotal role in tumor progression. Because of the efficacy of …

In addition to the well-known estrogen receptor (ER) and human epidermal growth factor
receptor 2, the androgen receptor (AR) is also a potential drug target in breast cancer …

Abstract 16α-[18 F] Fluoro-17β-estradiol ([18 F] FES) and 21-[18 F]-Fluoro-16α, 17α-[(R)-(1'-
α-furylmethylidene) dioxyl]-19-norpregn-4-ene-3, 20-dione ([18 F] FFNP) are being …